OCULAR HYPERTENSION TREATMENT STUDY (OHTS)

眼压过高治疗研究 (OHTS)

• 批准号: 6138189
• 负责人: TERRY J BERGSTROM
• 金额: $ 4.84万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-01-01 至 2003-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6138189
• 关键词: African American; beta antiadrenergic agent; carbachol; chemoprevention; clinical trials; cooperative study; disease /disorder proneness /risk; dosage; drug administration routes; drug adverse effect; early diagnosis; epinephrine; eye disorder chemotherapy; eye fundus photography; eye pharmacology; glaucoma; glaucoma test; human subject; human therapy evaluation; intraocular pressure; longitudinal human study; mass screening; medical complication; miotic; optic disk; pilocarpine; prognosis; statistics /biometry; therapy compliance; vision disorders; visual fields

DESCRIPTION (Investigator's Abstract) "Glaucoma is one of the leading causes of blindness in the United States and other industrialized countries. It is now recognized that glaucoma is the leading cause of blindness among African Americans. It is also one of the most common causes of blindness in individuals above age 60, one of the fastest growing groups in the United States. Elevated intraocular pressure (IOP) has been noted to be the key risk factor for the development of open angle glaucoma. However, there is no clear consensus on whether early treatment of elevated IOP prevents or delays the onset of open-angle glaucoma. This is an application to become a participating Clinical Center in the Ocular Hypertension Treatment Study (OHTS), a long-term, randomized, multicenter clinical trial to determine whether medical reduction of IOP prevents or delays the onset of glaucomatous optic nerve and/or visual field damage in ocular hypertensive subjects. The complete details of the OHTS rationale, design, and methods are contained in the OHTS Manual of Procedures. This proposal provides complete documentation of the ability of the University of Michigan to screen large numbers of ocular hypertensive patients and to enroll at least 50 eligible patients over a 24 month period. Documentation is provided of the capabilities of the proposed investigators and their staff for the performance of the study in accord with the details of the OHTS Manual of Procedures, the nature and extent of their commitment to the University of Michigan and the participation of community ophthalmologists."

描述（研究者的摘要） “青光眼是美国失明的主要原因之一 和其他工业化国家。 现在已经认识到青光眼是 非裔美国人失明的主要原因。 它也是之一 在60岁以上的个体中最常见的失明原因，其中之一 在美国增长最快的群体。 眼内压力升高 （IOP）已被认为是开发开放的关键风险因素 角度青光眼。 但是，关于早期是否有明确的共识 升高的IOP治疗可防止或延迟开眼界的发作 青光眼。 这是成为参与临床中心的应用 眼高血压治疗研究（OHTS），一项长期，随机的， 多中心临床试验以确定IOP的医学降低是否 防止或延迟青光眼视神经和/或视觉 眼部高血压受试者的现场损害。 完整的细节 OHTS理由，设计和方法包含在OHTS手册中 程序。 该建议提供了完整的文档 密歇根大学筛选大量眼部高血压 患者并在24个月内注册至少50名合格患者 时期。 提供了拟议调查员的功能的文件 以及他们的员工在研究表演的情况下符合详细信息 OHTS手册，其承诺的性质和程度 到密歇根大学和社区的参与 眼科医生。”